Each ml. contains ivermectin 10 mg.
Parasitic diseases are common in animals. Parasites can affect the skin, ears, stomach and intestines, and the internal organs including the heart, lungs and liver. Several drugs have been developed to kill or prevent parasites such as fleas, ticks, mites and worms. Ivermectin and related drugs are among the most effective of these.
Ivermectin is a parasite control drug. Ivermectin causes neurologic damage to the parasite, resulting in paralysis and death. Ivermectin has been used to prevent parasite infections, as with heartworm prevention, and to treat infections, as with ear mites.
Ivermectin is a prescription drug and can only be obtained from a veterinarian or by prescription from a veterinarian.
The injection is mainly applied to treat domestic animal’s diseases of gastrointestinal nematodes, hypoderma bovis, hypoderma lineatum, sheep nose bot, psoroptes ovis, sarcoptes scabiei var. Suis,sarcoptes ovis, fasciola(Liver Fluke), oestrus spp and the like.
Cattle: Ostertagia ostertagi (including inhibited o. ostertagi), o. lyrata, haemonchus placei, trichostrongylus axei, t. colubriformis, cooperia oncophora, c. punctata, c. pectinata, bunostomum phlebotomum, nematodirus helvetianus (adults only), n. spathiger (adults only), oesophagostomum radiatum, dictyocaulus viviparus, fasciola hepatica (adults only), hypoderma bovis, h. lineatum, linognathus vituli, haematopinus eurysternus, solenopotes capillatus, psoroptes ovis (syn. p. communis var. bovis), sarcoptes scabiei var. bovis. Sheep: Oestrus ovis, sarcoptes scabiei, psoregates var ovis, trichostrongylus axei, haemonchus sps., ostertagia sps., trichostrongylus sps., nematodirus sps., cooperia sps., bunostomum sps., strongyloides sps., oesophagastomum sps., chabertia sps., trichuris sps., dictyocaulus sps. Dogs: Sarcoptes scabiei, otodectes cynotis, toxascaris leonina, toxocara caninum / cati, uncinaria stenocephala, ancylostoma caninum, trichuris vulpis,dirifilaria (larval stages)
Usage and administration:
Cattle: 1.0 ml/50 kg body weight.
Sheep: 0.5 ml/25 kg body weight.
Dogs: 0.5 ml /25 kg body weight.
Medication should never be administered without first consulting your veterinarian. The dose for ivermectin varies from species to species and also depends on the intent of treatment. General dosing guidelines follow.
For dogs: Dose is 0.0015 to 0.003 mg per pound (0.003 to 0.006 mg/kg) once a month for heartworm prevention; 0.15 mg per pound (0.3 mg/kg) once, then repeat in 14 days for skin parasites; and 0.1 mg per pound (0.2 mg/kg) once for gastrointestinal parasites.
For cats: Dose is 0.012 mg per pound (0.024 mg/kg) once monthly for heartworm prevention.
The duration of administration depends on the condition being treated, response to the medication and the development of any adverse effects. Be certain to complete the prescription unless specifically directed by your veterinarian. Even if your pet feels better, the entire treatment plan should be completed to prevent relapse or prevent the development of resistance.
Side effect and contraindication:
While generally safe and effective when prescribed by a veterinarian, ivermectin can cause side effects in some animals. Ivermectin should not be used in animals with known hypersensitivity or allergy to the drug. Ivermectin should be used with caution in collie breeds or collie mixed breeds due to potential toxic effects. This is particularly true when using higher doses. Ivermectin should not be used in dogs that are positive for heartworm disease except under strict supervision of a veterinarian. Prior to starting a heartworm prevention containing ivermectin, the dog should be tested for heartworms. Ivermectin generally should be avoided in dogs less than 6 weeks of age. Ivermectin is relatively safe, but overdoses can occur if massive amounts are given or if the drug is given to heartworm positive dogs. Signs of overdose, including stumbling, tremors, blindness, disorientation or weakness, generally occur within 12 hours of overdose.
In heartworm positive dogs, supportive treatment for shock may be required. Ivermectin should be used with caution at high doses, a drug used to treat or prevent flea infestations.
The withdrawal time of 49 days has been established for ivermectin and clorsulon in cattle and sheep for slaughter. A withdrawal period for milk has not been established.
Keep this and all drugs out of the reach of children.
Storage and expired time：
Put in cool, dry and dark place.
SYNERA® is a simple-to-use prescription patch that helps prevent your child’s pain from certain needle sticks. CLICK BELOW FOR INDICATIONS, IMPORTANT SAFETY INFORMATION, AND LINKS TO PRESCRIBING INFORMATION AND PATIENT INFORMATION.
SYNERA® (lidocaine and tetracaine) Topical Patch is indicated for use on unbroken skin to help prevent the pain of needle sticks into superficial veins (apply for 20-30 minutes) and some superficial skin procedures (apply for 30 minutes).
IMPORTANT SAFETY INFORMATION
SYNERA® is not to be used in patients with a known history of sensitivity to lidocaine, tetracaine, numbing medications of the amide or ester type, or any other component of the product and in patients with para-aminobenzoic acid (PABA) hypersensitivity. Keeping a patch on longer than recommended or applying multiple patches at the same time or one right after the other could result in absorption of sufficient amounts of drug to result in serious adverse effects. Patients should not use SYNERA® if they have a history of methemoglobinemia.
Used SYNERA® patches contain a large amount of lidocaine and tetracaine (at least 90% of the initial amount). Chewing or swallowing a new or used SYNERA® patch may result in serious adverse effects. Store and dispose of SYNERA® out of the reach of children and pets.
SYNERA® should be used with caution in patients who may be more sensitive to the general effects on the body of lidocaine and tetracaine, particularly those who are seriously ill or weakened by illness, and those with reduced liver function. Patients with severe liver disease or missing adequate blood plasma enzymes are at greater risk of developing toxic plasma concentrations.
Do not use on body passages such as inside the nose or mouth or on areas with unhealthy, broken skin. Application to broken or inflamed skin may result in toxic blood concentrations of lidocaine and tetracaine. Allergic or extreme sensitivity (skin rash, swelling or hives, narrowing of airways, and shock) to the active or inactive components of SYNERA® can occur and should be managed by a medical professional. Seek immediate emergency help if any of these occur.
Avoid contact of SYNERA® with the eyes due to potential irritation or abrasion. If contact occurs, immediately wash out the eye with water or saline, and protect it until sensation returns.
The application of more than two SYNERA® patches at the same time or one right after another to children is not recommended as it has not been fully studied. Safety and effectiveness of SYNERA® have been established in patients 3 years of age and older.
Lidocaine, one of the numbing medications in SYNERA®, has been shown to prevent the growth of viruses and bacteria. The effect of SYNERA® on needle sticks into the skin for certain vaccines has not been determined.
The heating component contains iron powder, and the patch must be removed before some diagnostic procedures, including magnetic resonance imaging (MRI).
SYNERA® may lead to little or no feeling in the area of the skin where it is applied; therefore, patients should avoid trauma (rubbing, scratching, or exposure to heat or cold) before complete feeling returns.
SYNERA® should be used with caution in patients receiving certain heart medications and/or other local pain-preventing medications, because there may be additional toxic effects with lidocaine and tetracaine. In clinical studies involving 1,449 subjects treated with SYNERA®, the most common local reactions were redness of the skin (71%), pale skin (12%), and swelling (12%); these reactions were generally mild and resolved on their own soon after patch removal. There were no treatment- related serious adverse events. SYNERA® should be applied immediately after opening the pouch. Do not cut or remove the top cover of the patch as this could result in a burn injury.
If skin irritation or a burning sensation occurs during application, remove the patch and inform your doctor or nurse immediately.
Please see Full Prescribing Information including Instructions For Use —- https://www.synera.com/wp-content/uploads/2015/03/SYNERA_PI.pdf
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit https://www.fda.gov/medwatch, or call 1-800-FDA-1088.
©2016 Galen US Inc. PMR-SEP-2016-0279 September 2016